Targeted nanocarriers for the administration of immunosuppressive agents
US11214805B2 · kind B2 · utility
0Cited by
2References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 23, 2019 |
| Grant date | Jan 4, 2022 |
| Priority date | — |
| Expiry date | Aug 23, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a nanocarrier-containing immunosuppressive agent that is targeted to C3 breakdown products, integrin, or a combination thereof, to reduce the deleterious systemic effects of the immunosuppressive agent. Also disclosed is a method for suppressing an allo-immune response in a subject, such as one that can occur after an allograft transplantation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.